The central $9 price target is the arithmetic mean of four verified analyst price targets, which range from $8 to $10. At the latest close of about $3.62, reaching $9 implies upside of roughly 149% — a very large move requiring a full recovery and then new highs.
Starling Oncology (STLN) declined roughly 36% over the past 30 days, driven almost entirely by a single-session drop of nearly 46% on November 6 after third-quarter results. Third-quarter revenue of $169.77 million rose about 24% year over year and exceeded consensus, but the company narrowed its full-year revenue outlook to $650 million–$660 million from $650 million–$670 million.
NIVF shares slid from Friday's close of $0.4565 to $0.4119, a drop of -9.77%, during Monday's regular trading session. No verified news or fundamental catalyst found. The decline is consistent with the micro-cap's ongoing speculative collapse—it routinely swings by tens of percent, with recent sessions down -29.65% and -18.53%.
The central target of $1.00 is not an analyst price target; it reflects the $1.00 minimum bid price threshold required to maintain Nasdaq Capital Market listing compliance. The target was established through public discussion and the company's own repeated reverse splits, not through a verifiable analyst consensus.
GMRS slid during regular market hours, falling from a $12.44 prior close to about $11.50, a -7.56% decline. No verified news or fundamental catalyst found — the drop is consistent with pre-earnings de-risking ahead of Q3 results due after today's close, following last quarter's large EPS miss (-$1.84 vs. roughly $0.27 estimated) and elevated short interest.
The central $19 stock price target is the arithmetic mean of eight verified analyst price targets, rounded from roughly $19.38, and implies about 53% upside from the latest close. The analyst target range is unusually wide — from $14 (Morgan Stanley) to $35 (Goldman Sachs) — reflecting sharp disagreement about how quickly margins can improve.
ACM is AECOM, a global infrastructure consulting leader with an approximately $8.5 billion market capitalization, while CCM is Concord Medical Services Holdings, a China-based oncology healthcare provider with a market capitalization under roughly $25 million. The two companies operate in entirely different sectors and risk profiles, making this a study in contrasts between a diversified infrastructure franchise and a small-cap, single-market healthcare operator.
AirSculpt Technologies (AIRS) is scheduled to report results for the third quarter of fiscal 2026 (the period ended September 30, 2026) in early November. Management has guided to a single-digit comparable revenue decline in Q3, excluding London center sales from the prior year, as softer consumer demand trends persisted into July.
Brookdale Senior Living reported total revenue of $712.1 million for the third quarter of 2026, down 12.4% year over year and slightly below analyst consensus estimates. GAAP (Generally Accepted Accounting Principles) net loss narrowed to $0.06 per share , a sharp improvement from a $0.48 loss a year earlier, but still wider than the roughly $0.03 loss Wall Street had expected.
Net operating revenues rose 6.6% year over year to $407.97 million for the third quarter ended September 30, 2026. Reported GAAP (Generally Accepted Accounting Principles) net income declined to $13.64 million from $39.24 million, driven by unrealized losses in the marketable equity securities portfolio.
NUTX fell -5.53% during Thursday's regular session, slipping from a prior close of $193.64 to $182.93. The catalyst was the company's Q3 2026 results, released after Wednesday's close, showing revenue down -18.7% year over year and adjusted EBITDA down roughly -35%.
Agilon Health (AGL) dropped -3.52% during regular trading hours, sliding from a previous close of $113.77 to $109.77. No verified news or fundamental catalyst found — the decline is consistent with profit-taking after the prior session's +18.23% gap-up on a blowout Q3 earnings beat and raised 2026 guidance.
AVAH slipped from its prior close of $13.67 to about $13.28, a -2.85% decline, during regular market hours. No company-specific news or fundamental catalyst was reported; the move reflects continued profit-taking after Wednesday's +7.2% post-election surge, when a Democratic midterm sweep revived hopes of reversing Medicaid cuts.
Sonida Senior Living (SNDA) fell -3.96% during regular market hours, sliding from a previous close of $34.06 to about $32.71. The decline is a follow-through from the company's Q3 report released before the open on Nov. 5, which missed on EPS (-$0.72 vs -$0.42 expected) despite a revenue beat; shares tumbled -7.97% that day and kept giving back ground today.
PNTG dropped from $40.00 at its prior close to $37.02, a decline of -7.45%, during regular market hours. The slide extends the post-earnings selloff following Q3 2026 results and the November 5 call — compressed senior living margins, elevated employee benefits costs, a slight adjusted EPS miss, and a softer guidance tone.
WW International (WeightWatchers) fell -5.37% during regular trading, sliding from $12.84 at the prior close to $12.15. No verified news or fundamental catalyst found for today's move. The decline is consistent with profit-taking after the prior session's +5.85% earnings-driven pop and the stock's habit of swinging roughly 4-5% on most sessions.
JYNT dropped from a previous close of $7.37 to $6.74, a decline of -8.55%, with the slide beginning in after-hours trading following its earnings release and extending through today's regular session. The move followed Q3 2026 results reported after the Nov. 5 close: revenue of $13.6M missed estimates, and the company cut full-year system-wide sales and comp-sales guidance amid soft consumer spending.
Astrana Health (ASTH) fell -12.97% during regular market hours, dropping from a previous close of $39.01 to about $33.95. The selloff follows its Q3 2026 report, released after Thursday's close: adjusted EPS of $0.71 missed consensus by $0.17 on in-line revenue, and guidance was trimmed.
Brookdale Senior Living (BKD) dropped -14.52% to about $9.24 from a $10.81 prior close, with the decline occurring during regular market hours. The company reported Q3 results before the open: revenue of $712.1M and EPS of -$0.06 both missed estimates, and it cut full-year Adjusted EBITDA guidance to $495M-$502M and RevPAR growth to 7.4%-7.9%, citing slower occupancy growth and a community fire.
AMN Healthcare Services (AMN) fell sharply during regular trading on Thursday, dropping from a prior close of $47.42 to about $36.62, a decline of -22.78%. The slide followed Q3 results reported after Wednesday's close: despite a large beat (adjusted EPS $1.16 vs. ~$0.23 expected; revenue $717.3M), weak Q4 guidance implying a 10-12% year-over-year revenue decline as strike-related revenue fades, plus international nurse visa delays, triggered heavy profit-taking after the stock had roughly tripled year-to-date.